Featured Research

from universities, journals, and other organizations

Plant-made drug reverses breathing paralysis, study suggests

Date:
July 13, 2013
Source:
Arizona State University
Summary:
Paralytic drugs like succinylcholine are often used during surgery or when critically ill patients require endotracheal intubation. But if the drug is not swiftly cleared from the patient's system, the results can be deadly.

Paralytic drugs like succinylcholine are often used during surgery or when critically ill patients require endotracheal intubation. But if the drug is not swiftly cleared from the patient's system, the results can be deadly.

Related Articles


In a new study, Tsafrir Mor, a researcher at Arizona State University's Biodesign Institute and assistant professor in the School of Life Sciences, shows that the plant-produced recombinant human enzyme butyrylcholinesterase (BChE) can rapidly reverse paralysis of the airways -- or apnea -- caused by succinylcholine.

The results, recently reported in the journal PLOS ONE, suggest an expanded role for trauma techniques, like rapid sequence intubation, as well as other methods involving the use of succinylcholine, particularly in the pre-hospital arena, where a speedy intervention can mean the difference between life and death. Given the variety and frequency of conditions involving failed airways, a means of reversing succinylcholine-induced apnea may have profound implications.

"BChE is a promiscuous enzyme that can function as an effective, safe and versatile bioscavenger, but its use has been hampered by its availability," Mor says. "Plants expressing recombinant human BChE may provide the answer for this limitation."

The new findings build on earlier work by Mor's group, which demonstrated the potential for plant-made BChE to reverse the effects of organophosphate poisons, including pesticides and weaponized nerve agents. Possibilities also exist for reversing the effects of acute cocaine overdose or using plant-derived BChE as a cocaine prophylactic, dampening the drug's euphoric effects and thereby discouraging use.

Succinylcholine is a neuromuscular blocking agent, commonly used in conjunction with a sedative during anesthesia or to allow intubation to be carried out on an emergency basis. Succinylcholine is the drug of choice for such procedures due to the rapid onset and short duration of its effects, as it is rapidly cleared by the patient's serum BChE.

In certain patients however, clearance can be dangerously prolonged, leading to succinylcholine-induced apnea that can last several hours. The phenomenon has been recognized since the 1950s and may occur as a result of genetic factors or as an acquired condition. In either case, it is generally the result of a deficiency in the serum enzyme BChE.

Because of concerns regarding patient sensitivity to succinylcholine, use of the drug as an anesthetic in pre-hospital situations has been controversial. Lacking hospital resources to deal with patients exhibiting butyrylcholinesterase deficiency, first responders are often reluctant to undertake the risks involved in emergency endotracheal intubation. Currently, cases of post-succinylcholine apnea are typically managed in hospital settings through supportive care, due to a lack of safe, effective and plentiful reversing agents.

About one in 1800 administrations of succinylcholine result in prolonged apnea. Around 65 percent of these cases result from decreased hydrolysis of succinylcholine by BChE and its variants. Inability to hydrolyze succinylcholine can have a hereditary basis, with some patients carrying an abnormal variant of one or more genes responsible for succinylcholine hydrolysis. Depending on the particular mutation, these individuals can experience periods of apnea ranging from around two hours for those carrying one copy of the non-functional allele, to three to four hours or more for those carrying two copies.

Additionally, BChE deficiency can be acquired as a result of conditions including cirrhosis, burns, liver cancer or malnutrition, or as a side effect of some commonly prescribed drugs, including oral contraceptives. The authors of the current study note that the ability to reverse hereditary or acquired apnea could significantly improve the safety margin for succinylcholine, rapidly restoring normal breathing to an affected patient.

Rapidly and safely reversing succinylcholine-induced apnea may open new possibilities for respiratory management, including new devices or medications for acute trauma situations. Such strategies could be particularly useful in cases of upper airway obstruction, where neuromuscular blockage carries a risk of airway collapse and suffocation.

Although missing or nonfunctional serum BChE could potentially be replaced using blood products, including stabilized serum, fresh frozen plasma or purified enzyme, such treatment carries the risk of blood-borne pathogens and prions as well as more common complications associated with transfusion. Mor notes that purification of the enzyme for various applications would necessitate dedicating the entire annual U.S. blood supply to produce a sufficient number of doses.

The solution underlined in the new study involves producing recombinant butyrylcholinesterase in transgenic tobacco plants. The plants are modified to synthesize the BChE enzyme in their leaves. In a series of experiments involving both mice and guinea pigs, Mor demonstrates the ability of plant-derived BChE to reverse post-succinylcholine apnea. The method can be rapidly scaled up to provide a significant stockpile of the apnea-reversing agent, without the costs and attendant risks associated with purifying butyrylcholinesterase from blood products.


Story Source:

The above story is based on materials provided by Arizona State University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Brian C. Geyer, Katherine E. Larrimore, Jacquelyn Kilbourne, Latha Kannan, Tsafrir S. Mor. Reversal of Succinylcholine Induced Apnea with an Organophosphate Scavenging Recombinant Butyrylcholinesterase. PLoS ONE, 2013; 8 (3): e59159 DOI: 10.1371/journal.pone.0059159

Cite This Page:

Arizona State University. "Plant-made drug reverses breathing paralysis, study suggests." ScienceDaily. ScienceDaily, 13 July 2013. <www.sciencedaily.com/releases/2013/07/130713122803.htm>.
Arizona State University. (2013, July 13). Plant-made drug reverses breathing paralysis, study suggests. ScienceDaily. Retrieved October 30, 2014 from www.sciencedaily.com/releases/2013/07/130713122803.htm
Arizona State University. "Plant-made drug reverses breathing paralysis, study suggests." ScienceDaily. www.sciencedaily.com/releases/2013/07/130713122803.htm (accessed October 30, 2014).

Share This



More Health & Medicine News

Thursday, October 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Microsoft Launches Fitness Band After Accidental Reveal

Microsoft Launches Fitness Band After Accidental Reveal

Newsy (Oct. 30, 2014) Microsoft accidentally revealed its upcoming fitness band on Wednesday, so the company went ahead and announced it. Video provided by Newsy
Powered by NewsLook.com
Bracing to Meet a Killer: Aid Workers Prep for Ebola in Geneva

Bracing to Meet a Killer: Aid Workers Prep for Ebola in Geneva

AFP (Oct. 30, 2014) At the International Federation of Red Cross and Red Crescent Societies, around 30 doctors, nurses, lab technicians and water and sanitation workers are gathered for a crash-course in how to safely deal Ebola. Duration: 01:31 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins